Drug Database
LY

lysine salicylate (lysine salicylate / Dolorosan)

✓ Approved

VUFB · Small Molecule · Small Molecule

What is lysine salicylate?

lysine salicylate is a small molecule developed by VUFB. It is approved for therapeutic indications via unknown.

Drug Profile

Brand Nameslysine salicylate, Dolorosan
CompanyVUFB
Drug ClassSmall Molecule
RouteUnknown
StatusApproved

Therapeutic Indications

lysine salicylate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Gastrointestinal disordersAbdominal pain✓ Approved

Related Research Articles

PubMedCase reports in urology2026-09-20

Cystinuria Diagnosed at Age 67 Following a 49-Year Diagnostic Delay: A Reminder of Indolent Cystinuria in Adult Urolithiasis-A Case Report.

Jeffery Sarah S, Tyson Matthew M, McAuley Laura L, Harty John J

Cystinuria is a genetic disorder resulting from mutations in the SLC3A1 and SLC7A9 genes, which impair the reabsorption of cystine, ornithine, lysine and arginine and lead to increased urinary excretion of cystine. Elevated urinary cystine concentration promotes precipitation and subsequent stone formation, manifesting as recurrent urolithiasis. Cystinuria is the most common genetic condition that results in urolithiasis and is typically diagnosed in adolescence. In this case report, we present a male patient diagnosed with cystinuria at the age of 67. The patient presented with acute left flank pain, and noncontrast CT imaging of the urinary tract identified left renal calculi and multiple proximal ureteric stones, accompanied by hydronephrosis. Ureteroscopy revealed dense calculi resistant to laser fragmentation, and stone analysis confirmed a 100% cystine composition. The patient reported a previous stone event at age 18 with spontaneous passage but had remained stone-free for nearly 50 years and had no prior diagnosis of cystinuria. This case demonstrates that cystinuria, although typically diagnosed in childhood or adolescence, can be diagnosed in older adults with recurrent or resistant urolithiasis. Clinicians should maintain a high index of suspicion for cystinuria in adult patients with unexplained or refractory stone disease, and stone analysis remains essential for accurate diagnosis. Optimal management centres on preventing recurrent stone formation through aggressive fluid intake, dietary modifications and medical alkalinisation of urine. Multidisciplinary follow-up is important to reduce the risk of renal impairment and potential later need for nephrectomy.

PubMedJournal of molecular modeling2026-09-19

Computational Modeling and MM-PBSA-Based Molecular Dynamics Investigation of Unexplored tRNA Isoleucine Lysidine Synthetase from Mycobacterium tuberculosis with Hyperbranched Amoxicilloyl-Poly-L-Lysine.

Nath Priyanka P, Choudhury Bipasha B, Peerzade Saquib Ahmed M A SAMA, Goyal Arun A et al.

Integrated in-silico approach employed to characterize tRNA isoleucine lysidine synthetase enzyme (MtTilS; UniProt P9WG52), which is essential for protein synthesis in Mycobacterium tuberculosis and to design Amoxicilloyl-Poly-L-Lysine (APL) compounds as putative inhibitors. MtTilS (323 aa) contained TilS (9-230), substrate-binding (249-323) domains and conserved SGGXDS motif. Homology modeling revealed Rossmann-like α/β/α fold, favourable validation (ERRAT 96%, VERIFY3D 81.8%, ProSA - 9.96) and positively charged N-terminal groove (druggability ~ 0.8). APL compounds showed predicted antibacterial activity, high aqueous solubility and low predicted toxicity. Docking prioritized APL-3 (- 7.0 kcal/mol) as favourable inhibitor. Three independent 200 ns molecular dynamics simulations showed preservation of protein fold and ligand association. Cluster analysis indicated convergence toward dominant conformational states. Principal component analysis (PCA) showed broader but reproducible conformational sampling. Free energy landscape (FEL) analysis identified low-energy conformational basins. Dynamic cross-correlation matrix (DCCM) analysis showed conserved correlated residue motions. MM-PBSA indicated favourable binding free energy (-60.0 ± 24.6 kJ/mol) with van der Waals and electrostatic interactions as major contributors while Arg101, Met145, Tyr105, Arg146, Arg140 and Arg219 as major energetic contributors. Preliminary computational evidence supporting MtTilS as target and APL-3 as putative inhibitor candidate necessitating further experimental validation. MtTilS sequence analyzed using CDD, BLAST and MEGA-X. Structure modeled with Phyre2 minimized using Swiss-PDB Viewer/GROMOS96, validated with SAVES-6.0 and visualized in PyMOL-2.0. Binding pockets and druggability predicted using HDOCK and DoGSiteScorer. APL designed in Avogadro (MMFF94) and screened using AntiBac-Pred. ADME/toxicity assessed using SwissADME and ProTox-II. Docking performed with AutoDock Vina-1.2.0 and MD using GROMACS (CHARMM36ff). Trajectories analyzed by PCA, FEL, DCCM and MM/PBSA.

PubMedCancer treatment and research communications2026-09-19

Viral exploitation of p300/CBP at the virus-cancer interface: Chromatin regulation, oncogenesis, immune evasion, and therapeutic targeting.

Atoom Ali M AM, Rizaev Jasur J, Polatova Djamila D, Patel Pareshkumar N PN et al.

The transcriptional coactivators p300 and CREB-binding protein (CBP) integrate chromatin remodeling, enhancer activity, lysine acetylation, immune signaling, and tumor-suppressor control, making them recurrent targets of viral proteins. This narrative review examines p300/CBP at the virus-cancer interface, prioritizing HTLV-1, high-risk HPV, EBV, KSHV, HBV, and HCV. We distinguish physical interaction, biochemical modulation, functional reliance, and therapeutic confirmation and compare how viral factors recruit, inhibit, degrade, or redistribute these coactivators during persistence, immune evasion, and malignant progression. Evidence from non-oncogenic viruses is retained only when it clarifies conserved mechanisms or therapeutic liabilities. Preclinical studies support catalytic, interaction-selective, and virus-specific targeting strategies, but human evidence is limited to early-phase PRI-724/OP-724 antifibrotic studies in viral cirrhosis. Because p300/CBP also support normal transcription and antiviral immunity, systemic inhibition may cause substantial toxicity. Overall, p300/CBP are best viewed as context-dependent regulatory hubs, and translation will require paralog-, domain-, and disease-specific validation.

PubMedZhonghua yi xue za zhi2026-09-19

[Mechanism of ethionine-induced neural tube defects via regulation of the Wnt/β-catenin pathway through the KDM5A/H3K4me3 axis].

Gao J J JJ, Mu Q Q, Zhang H H, Zhang X B XB et al.

Objective: To explore the molecular mechanisms by which ethionine induces neural tube defects (NTD) through regulating the lysine demethylase 5A (KDM5A)/trimethylated lysine 4 of histone H3 (H3K4me3) axis and modulating the Wnt/β-catenin signaling pathway. Methods: Specific pathogen-free adult male and female C57BL/6 mice (80 females and 35 males) were housed overnight in a 2∶1 female-to-male ratio. Vaginal plugs were examined the following morning to confirm pregnancy. Pregnant mice were randomly divided into two groups: the ethionine experimental group (ethionine group) and the control group. At embryonic day 7.5 (E7.5), the ethionine group received a single intraperitoneal injection of ethionine (500 mg/kg) to establish the NTD model, while the control group was injected with an equal volume of normal saline, with 21 mice in each group. At E10.5, pregnant mice were sacrificed and embryos were collected for observation and photography under a stereomicroscope. Brain tissues from embryos of both groups were harvested for transcriptome sequencing. The expression levels of KDM5A, H3K4me3, Wnt/β-catenin pathway components [β-catenin, transcription factor 4 (TCF4), axis inhibition protein 2 (Axin2), phosphorylated glycogen synthase kinase 3β (p-GSK3β)], and cell proliferation-related proteins [G1/S-specific cyclin-D1 (Cyclin D1), proliferating cell nuclear antigen (PCNA), Myc oncogene (c-Myc)] were assessed by Western blotting, real-time quantitative polymerase chain reaction (RT-qPCR), and immunofluorescence. An additional KDM5A-specific inhibitor GSK-4J treatment group (GSK-4J group) and ethionine combined with GSK-4J treatment group (ethionine+GSK-4J group) were included to verify the regulatory role of the KDM5A/H3K4me3 axis. The pregnant mice in the GSK-4J group received intraperitoneal injection of GSK-4J (7 mg/kg) and the ethionine+GSK-4J group were injected with both 7 mg/kg GSK-4J and 500 mg/kg ethionine, with 12 mice in each group. Comparisons between the two groups were performed using independent samples t-test, one-way ANOVA was applied to evaluate the overall differences among multiple groups, and Tukey's honestly significant difference test was adopted for pairwise post-hoc comparisons. Results: The ethionine treated group exhibited 48.79% (121/248) incidence of incomplete brain structure and morphological malformations, while the malformation rate in the control group was 3.73% (10/268), with a statistically significant difference (P<0.001). Compared with the control group, the ethionine group showed elevated KDM5A mRNA and protein levels, accompanied by reduced H3K4me3 modification levels (all P<0.001); protein expression of β-catenin, TCF4, and Axin2 were decreased (P<0.01, P<0.05), whereas p-GSK3β was increased (P<0.01). Following GSK-4J intervention, the expression of β-catenin, TCF4, and Axin2 was partially restored (all P<0.01), and the percentage of Cyclin D1-positive cells, as well as the expression of PCNA and c-Myc were increased (all P<0.05). Conclusion: Ethionine participates in NTD development by upregulating KDM5A to decreased H3K4me3 levels, inhibiting Wnt/β-catenin signaling pathway, and reducing neuroepithelial cell proliferation. Thus, targeting the KDM5A/H3K4me3 axis may provide a new strategy for the prevention and treatment of NTD.

PubMedMolecular cancer2026-09-19

KMT9 drives T cell exclusion and dysfunction by promoting PMN-MDSCs infiltration and ARG1 expression in prostate cancer.

Peñarando Jon J, Willmann Dominica D, Sum Manuela M, Jia Yanhan Y et al.

Immunotherapy has emerged as a revolutionary therapeutic approach to treat cancer showing remarkable clinical responses. However, its efficacy in solid tumours such as prostate cancer (PCa) remains very limited due to a highly immunosuppressive tumour immune microenvironment (TIME) that hampers cytotoxic T cell infiltration and activity. Here, we show that lysine methyltransferase 9 (KMT9) governs the formation of an immunosuppressive TIME in PCa. KMT9 regulates the expression of tumour-secreted myeloid-attracting C-X-C motif chemokine receptor 2 (CXCR2) ligands such as C-X-C motif chemokine ligand 5 (CXCL5) thereby promoting the infiltration of immunosuppressive polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) within tumours. These changes collectively result in decreased activation and exclusion of cytotoxic T cells from tumour glands. Furthermore, we demonstrate that KMT9 confers tumour cell-resistance to T cell cytotoxicity by regulating expression of arginase 1 (ARG1). Accordingly, KMT9α ablation results in inhibition of prostate tumour growth accompanied by a massive reduction of PMN-MDSC recruitment and a significant increase in cytotoxic T cell activation and infiltration of the prostate tumour glands. Together, we uncovered KMT9 as a regulator of immune evasion that promotes an immune-excluded TIME in prostate tumours. Furthermore, our findings establish KMT9 as a therapeutic target to reprogram the immunosuppressive landscape and potentially improve the clinical efficacy of current immunotherapies.

PubMedJournal of virological methods2026-09-19

Genetic characterization of Orf virus isolates targeting PACR gene: Optimization of a diagnostic PCR for host-specific differentiation of goat and sheep origin isolates.

Karki Monu M, Kumar Amit A, Venkatesan Gnanavel G

Parapoxviruses are known for its unique feature of carrying a number of virulence genes in their large genome and deploy them as a weapon to evade host immune response. One of its unique gene is Poxviral anaphase promoting complex regulator (PACR) from the left terminal of the genome named as ORF014. This PACR protein basically mimics the subunit, APC11 of anaphase promoting complex (APC)/cyclosome of the host cell. Orf virus is the prototypic member of Parapoxvirus genera and causes mostly localized infection in animals as well as humans. Considering the importance of gene in ORFV replication and virulence, and the endemicity of the disease in the country affecting sheep and goats, we designed a study to genetically characterize different ORFV isolates from different geographical parts of India. Interestingly, multiple sequence alignment of the gene revealed that sheep and goat isolates encoded different ORF lengths of gene i.e. 282bp and 288bp respectively with an additional two amino acids namely valine and lysine at 7th and 8th position in ORFV isolates of goat origin only. Likewise, the difference was also reflected in phylogenetic tree as the sheep and goat isolates of ORFV were clustered into two groups. Based on these salient findings, the difference in sequences was exploited to design species-specific primers for the development of diagnostic PCR to differentiate sheep and goats ORFV isolates. On evaluation of clinical samples and cell culture isolates of ORFV, PCR clearly distinguished them as sheep and goat isolates. The comparable relative specificity and sensitivity of the ORF014 based diagnostic PCR with in-use PCR also revealed a refine potential for epidemiological insights of parapoxviruses. This study seems to have proposed for the first time a basis for differentiating the ORFV isolates by their origin of species.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about lysine salicylate